Eltrombopag ( DrugBank: Eltrombopag )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
60	再生不良性貧血	31
63	特発性血小板減少性紫斑病	86
65	原発性免疫不全症候群	2
284	ダイアモンド・ブラックファン貧血	1
285	ファンコニ貧血	1

60. 再生不良性貧血

臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166

diseases per page:

Showing 1 to 10 of 31 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200060098	2022-05-05	2022-05-18	A retrospective study to assess the efficacy and safety of eltrombopagin combination with immunosupp ...	A retrospective study to assess the efficacy and safety of eltrombopagin combination with immunosupp ...	Aplastic anemia	Experimental group:Eltrombopag combined with immunosuppressive therapy (IST);Control group:IST;	The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine	NULL	Pending	16	80	Both	Experimental group:132;Control group:66;	Phase 4	China
2	ChiCTR2100054957	2021-12-24	2021-12-29	A prospective controlled study evaluating the efficacy and safety of eltrombopagcombined with immuno ...	A prospective controlled study evaluating the efficacy and safety of eltrombopagcombined with immuno ...	Aplastic anemia (AA)	Group 1:Eltrombopag + Immunosuppressive Therapy (IST);Group 2: Immunosuppressive Therapy (IST);	The First Affiliated Hospital of Zhejiang Medical University	NULL	Recruiting	16	80	Both	Group 1:132;Group 2:66;	Phase 4	China
3	NCT05049668 (ClinicalTrials.gov)	October 2021	13/9/2021	RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial	Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study ...	Severe Aplastic Anemia	Drug: ATGAM plus CsA with or without Eltrombopag	European Society for Blood and Marrow Transplantation	NULL	Enrolling by invitation	N/A	N/A	All	197		France
4	ChiCTR2100043229	2021-02-22	2021-02-09	A Single-Center, Single-Arm, Phase II Clinical Study of the Efficacy and Safety of Cyclosporine Comb ...	A Single-Center, Single-Arm, Phase II Clinical Study of the Efficacy and Safety of Cyclosporine Comb ...	Aplastic anemia	Durgs Group:Elrombopag combined with Cyclosporine;	Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences	NULL	Recruiting	18	85	Both	Durgs Group:61;	Phase 2	China
5	NCT04328727 (ClinicalTrials.gov)	November 4, 2020	9/3/2020	Combination of EltrombopagWith Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic ...	A Non-randomized, Open Label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltr ...	Severe Aplastic Anemia (SAA)	Drug: eltrombopag;Drug: rabbit anti-thymocyte globulin (r-ATG);Drug: cyclosporine A (CsA)	Novartis Pharmaceuticals	NULL	Active, not recruiting	6 Years	N/A	All	36	Phase 2	China;Japan;Korea, Republic of;Taiwan
6	NCT04403321 (ClinicalTrials.gov)	July 1, 2020	21/5/2020	Efficacy and Safety of Eltrombopag+ Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Pat ...	Efficacy and Safety of Eltrombopag+ Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Pat ...	Aplastic Anemia;Drug Effect	Drug: Tacrolimus;Drug: Placebo (for Tacrolimus)	Peking Union Medical College Hospital	NULL	Completed	14 Years	85 Years	All	114	Phase 2	China
7	NCT04304820 (ClinicalTrials.gov)	May 7, 2020	10/3/2020	Early Initiation of Oral Therapy With Cyclosporine and Eltrombopagfor Treatment Naive Severe Aplasti ...	Early Initiation of Oral Therapy With Cyclosporine and Eltrombopagfor Treatment Naive Severe Aplasti ...	Severe Aplastic Anemia	Drug: Eltrombopag;Drug: Cyclosporine;Drug: Horse-Anti-thymocyte-Globulin	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Recruiting	3 Years	N/A	All	39	Phase 2	United States
8	NCT03988608 (ClinicalTrials.gov)	December 9, 2019	13/6/2019	Study to Assess the Safety and Efficacy of Eltrombopagin Chinese Refractory or Relapsed Severe Aplas ...	A Non-randomized, Open-label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltr ...	Aplastic Anemia	Drug: Eltrombopag 25 mg	Novartis Pharmaceuticals	NULL	Active, not recruiting	18 Years	N/A	All	20	Phase 2	China
9	JPRN-jRCTs071190032	26/11/2019	21/10/2019	W-JHS AA02	Investigation on the effectiveness of rabbit ATG + cyclosporine + eltrombopagtherapy for patients wi ...	aplastic anemia	1. The administration of rATG; 2.5 mg/kg, iv. daily, day 1 - day 5 + CsA; 5 mg/kg, po. bid (before b ...	Ishiyama Ken	NULL	Recruiting	>= 18age old	< 80age old	Both	60	Phase 2	Japan
10	EUCTR2016-002814-29-IT (EUCTR)	14/06/2019	24/05/2021	SOAR, Interventional phase II single-arm study to assess efficacy and safety of eltrombopagcombined ...	SOAR, Interventional phase II single-arm study to assess efficacy and safety of eltrombopagcombined ...	First-line severe aplastic anaemia MedDRA version: 20.0;Level: PT;Classification code 10002967;Term: ...	Trade Name: SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE Product Name: Sandimmun Neoral Product C ...	NOVARTIS PHARMA AG	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Hungary;Hong Kong;Mexico;Spain;Thailand;Brazil;Korea, Democratic People's Republic of;Turkey;Netherl ...

First Previous1 2 3 4Next Last

先頭へ

63. 特発性血小板減少性紫斑病

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

diseases per page:

Showing 1 to 10 of 86 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05653219 (ClinicalTrials.gov)	February 2, 2023	23/11/2022	A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopagin Primary Immu ...	A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltromb ...	Primary Immune Thrombocytopenia	Biological: Ianalumab;Drug: Eltrombopag;Drug: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	150	Phase 3	Czechia;Hungary;Korea, Republic of;Singapore;United Kingdom
2	EUCTR2022-001627-32-ES (EUCTR)	23/01/2023	01/11/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	United States;Philippines;Taiwan;Thailand;Spain;Italy;India;France;Malaysia;Australia;Netherlands;Ch ...
3	EUCTR2022-001627-32-NL (EUCTR)	29/12/2022	31/10/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	United States;Philippines;Taiwan;Thailand;Spain;Italy;India;France;Malaysia;Australia;Netherlands;Ch ...
4	EUCTR2022-001627-32-CZ (EUCTR)	05/12/2022	20/10/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	Singapore;United States;Czechia;Malaysia;Thailand;Austria;Netherlands;China;Korea, Republic of;Franc ...
5	NCT05583838 (ClinicalTrials.gov)	November 22, 2022	12/10/2022	A Randomized Trial Comparing Optimized rhTPO Treatment With EltrombopagTreatment in Pre-treated ITP ...	Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus EltrombopagTreatment in Previo ...	Previously Treated Primary Immune Thrombocytopenia	Drug: rhTPO;Drug: Eltrombopag	Institute of Hematology & Blood Diseases Hospital	The Second Hospital of Hebei Medical University;Xijing Hospital;The Affiliated Hospital of Inner Mon ...	Recruiting	18 Years	85 Years	All	175	Phase 4	China
6	NCT04812483 (ClinicalTrials.gov)	September 1, 2022	1/3/2021	Immunomodulation With Eltrombopag in ITP	Immunomodulation in Young and Midlife Adults With Newly Diagnosed Primary Immune Thrombocytopenia (I ...	Primary Immune Thrombocytopenia (ITP)	Drug: Eltrombopag (Revolade®);Drug: standard therapy (without eltrombopag): HD-DXM	University Children's Hospital Basel	Stiftung zur Förderung medizinischer und biologischer Forschung;Novartis Pharmaceuticals;University ...	Recruiting	18 Years	55 Years	All	24	Phase 2	Switzerland
7	NCT05369377 (ClinicalTrials.gov)	June 1, 2022	6/5/2022	Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia	Zanubrutinib and Eltrombopagas Second-line Treatment for Patients With Immune Thrombocytopenia: a Mu ...	Immune Thrombocytopenia	Drug: Zanubrutinib;Drug: Eltrombopag	Peking University People's Hospital	Beijing Hospital;The Sixth Medical Center of PLA General Hospital;Beijing Aerospace General Hospital ...	Not yet recruiting	18 Years	70 Years	All	150	Phase 2	China
8	ChiCTR2000040991	2022-03-02	2020-12-16	Cyclosporine A combined with eltrombopagin the treatment for primary immune thrombocytopenia: a pros ...	Cyclosporine A combined with eltrombopagin the treatment for primary immune thrombocytopenia: a pros ...	primary immune thrombocytopenia	experimental group:Cyclosporine A combined with eltrombopag;	The First Affiliated Hospital, College of Medicine, Zhejiang University	NULL	Recruiting	18	75	Both	experimental group:28;	Phase 4	China
9	ChiCTR2100051890	2021-11-01	2021-10-09	Efficacy and safety analysis of Tetrasip in refractory primary immune thrombocytopenia	Efficacy and safety analysis of Tetrasip in refractory primary immune thrombocytopenia	Primary Immune Thrombocytopenia	Experimental group:Telitacicept;Control group 1:Eltrombopag;Control group 2:Rituximab;	The Second Affiliated Hospital of Kunming Medical University	NULL	Pending	18	60	Both	Experimental group:20;Control group 1:20;Control group 2:20;	Phase 4	China
10	NCT04917679 (ClinicalTrials.gov)	September 1, 2020	1/12/2020	Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP	EltrombopagPlus Diacerein vs Eltrombopagin Adult Primary Immune Thrombocytopenia: a Multicenter Rand ...	Thrombocytopenia	Drug: Eltrombopag plus diacerein;Drug: Eltrombopag	Qilu Hospital of Shandong University	NULL	Recruiting	18 Years	N/A	All	100	Phase 2	China

First Previous1 2 3 4 5…9Next Last

先頭へ

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04371939 (ClinicalTrials.gov)	November 5, 2019	29/4/2020	Efficacy and Safety of Romiplostim Versus Eltrombopagin the Treatment of Thrombocytopenia in Patient ...	Randomized, Two-arm Single-center Phase II Clinical Trial Comparing the Efficacy and Safety of Romip ...	Wiskott-Aldrich Syndrome	Drug: Romiplostim;Drug: Eltrombopag	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	NULL	Recruiting	N/A	18 Years	All	30	Phase 2	Russian Federation
2	NCT00909363 (ClinicalTrials.gov)	June 2009	27/5/2009	Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients	Effects Of EltrombopagOn Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-A ...	Wiskott-Aldrich Syndrome;Thrombocytopenia;Bleeding	Drug: Promacta;Diagnostic Test: blood drawing in patients with WAS;Diagnostic Test: blood drawing in ...	Weill Medical College of Cornell University	Novartis Pharmaceuticals	Terminated	3 Months	80 Years	Male	24	Phase 2	United States

First Previous1Next Last

284. ダイアモンド・ブラックファン貧血

臨床試験数 : 36 / 薬物数 : 95 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04269889 (ClinicalTrials.gov)	December 1, 2020	13/2/2020	Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag	Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag	Anemia, Diamond-Blackfan	Drug: Eltrombopag	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Active, not recruiting	2 Years	N/A	All	15	Phase 1/Phase 2	United States

First Previous1Next Last

285. ファンコニ貧血

臨床試験数 : 62 / 薬物数 : 93 - (DrugBank : 30) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 144

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03206086 (ClinicalTrials.gov)	November 2, 2018	30/6/2017	Eltrombopag for People With Fanconi Anemia	Eltrombopag for Patients With Fanconi Anemia	Fanconi Anemia	Drug: Eltrombopag	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Recruiting	2 Years	N/A	All	35	Phase 2	United States

First Previous1Next Last

先頭へ